Healthcare Sales & Marketing Network News: Focalin XR

Searching News Database: Focalin XR

HSMN NewsFeed - 24 Feb 2017
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage(R) XR
Biopharmaceuticals Generics FDA

HSMN NewsFeed - 3 Feb 2017
Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista(TM) (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Nov 2016
Intellipharmaceutics Submits New Drug Application for Rexista(R) (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Jul 2008
Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day
Biopharmaceuticals

HSMN NewsFeed - 20 Nov 2007
Barr Confirms Patent Challenge of Focalin(R) XR
Biopharmaceuticals Generics

Return to NewsFeed

Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 3 additional stories matching:
Focalin XR
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.